This study is looking at treatments for high-risk cervical cancer, a type of cancer affecting the cervix, which is the lower part of the uterus. The study is comparing two treatment plans. One plan uses chemotherapy and a medicine called pembrolizumab before radiation, followed by more pembrolizumab. The other plan uses chemotherapy and radiation at the same time, followed by pembrolizumab. Pembrolizumab is a type of immunotherapy, which helps the immune system attack cancer cells.

Key Points:

• **Study Length**: Treatment involves cycles over several weeks, with follow-ups for up to 5 years.
• **Visits**: Regular hospital visits for treatment and scans are needed.
• **Risks**: Possible side effects include fatigue, nausea, or serious reactions.

Before joining, consider the commitment needed for frequent hospital visits and the potential side effects. The study aims to find out if adding more treatments will help patients live longer without the cancer getting worse.